Actelion Pharmaceuticals Ltd : Actelion's ponesimod successful in mid-stage
trial in patients with moderate to severe chronic plaque psoriasis - Ponesimod
to proceed to Phase III clinical development in psoriasis
Actelion Pharmaceuticals Ltd / Actelion's ponesimod successful in mid-stage
trial in patients with moderate to severe chronic plaque psoriasis - Ponesimod
to proceed to Phase III clinical development in psoriasis . Processed and
transmitted by Thomson Reuters ONE. The issuer is solely responsible for the
content of this announcement.
ALLSCHWIL/BASEL, SWITZERLAND - 18 December 2012 - Actelion (SIX: ATLN)
announced today that its selective S1P[1] modulator, ponesimod, successfully
met the primary endpoint - the proportion of patients with at least 75%
improvement in Psoriasis Area and Severity Index (PASI) from baseline (PASI75)
at week 16 - in a double blind, placebo-controlled study conducted in 326
patients with moderate to severe chronic plaque psoriasis.
Results of the primary endpoint were highly statistically significant with
both tested doses. With Ponesimod 20 mg, 46 % of patients improved by at least
75 % at week 16 (p<0.0001 versus placebo). With Ponesimod 40 mg, 48.1% of
patients improved by at least 75 % at week 16 (p<0.0001 versus placebo). An
improvement by at least 75 % was observed at week 16 in 13.4% of the placebo
treated patients. Both doses were administered once daily.
At the end of induction, ponesimod patients improving at least 50% or more in
their PASI score at week 16 were re-randomized to either continuation of the
same dose of ponesimod, or to placebo.
After the initial 16 week induction phase of the study, further improvement
was seen with ponesimod during the 12-week double-blind, placebo-controlled
maintenance period. Among patients continuing on ponesimod 20 and 40mg, 71%
and 77 % achieved PASI75 at the end of the study, respectively.
Efficacy was also demonstrated across other endpoints of the study, including
Physician Global Assessment (PGA) at week 16.
Guy Braunstein, M.D. and Head of Clinical Development at Actelion commented:
"This is the first time that this mechanism has demonstrated efficacy with
psoriasis patients. Analysis during the maintenance period of the study showed
patients continued to improve beyond the initial 16 week induction phase.
Having conducted such a large Phase II study we have the information we need
for the design of the pivotal Phase III program."
Safety and tolerability data from the study are consistent with the safety
profile of ponesimod observed in previous studies conducted including the
Phase II study with multiple sclerosis patients.[3] At initiation of ponesimod
treatment, transient reductions in heart rate and less frequently, a transient
effect on atrioventricular conduction were observed in the study as expected.
The most frequent adverse events (AEs) reported for ponesimod was
dose-dependent dyspnea and asymptomatic liver enzyme elevations. Overall,
there were no indications of an increased infection rate with ponesimod in the
study with the exposure to ponesimod up to 28 weeks. The safety data-base from
all studies with ponesimod, now comprises more than 1,100 patients and healthy
volunteers with some patients treated for up to 3.3 years.
Jean-Paul Clozel, M.D. and Chief Executive Officer commented: "We are excited
to now know that ponesimod, originating from Actelion's discovery effort, has
the potential to become an important treatment option in immune-mediated
disorders in addition to multiple sclerosis. Actelion will rapidly move
forward with the preparation of the pivotal program and discussions with
health authorities for the psoriasis indication."
Once full data analysis has been concluded, Actelion will discuss the details
of the upcoming Phase III program with health authorities. Actelion will
present the results of this dose-finding study through scientific
presentations and publications.
###
Notes to the Editor
About ponesimod in psoriasis
Ponesimod was studied in patients with moderate-to-severe psoriasis in a
multicenter, randomized, double-blind, placebo-controlled, parallel-group
trial that evaluated the efficacy, safety and tolerability of 2 dose levels of
ponesimod administered during 16 weeks. This induction period was followed by
a 12-week maintenance period during which patients treated with ponesimod and
reaching PASI50 at week 16 were treated either with ponesimod or placebo, for
a total of up to 28 weeks. This 326-patient study started enrollment in 2010
and was completed in November of 2012.
About the efficacy measurements used in the study
Efficacy of a potential therapy for psoriasis is commonly measured using the
Psoriasis Area and Severity Index (PASI). A reduction of at least 75% in PASI
from baseline is typically considered clinically meaningful by the CHMP and
clinicians [EMEA 2004]. The CHMP [EMEA 2004] recommends using two endpoints to
assess efficacy: PASI in conjunction with a validated, standardized global
score such as Physician's Global Assessment (PGA). In this mid stage
dose-finding study PASI has been chosen as the primary efficacy endpoint and
PGA as the secondary endpoint.
About Psoriasis
Psoriasis is a chronic, relapsing, inflammatory and immune-mediated skin
disease affecting about 1-3% of the population worldwide. Plaque psoriasis is
the most common form of psoriasis, constituting ~ 85% of cases. The most
characteristic skin lesions of chronic plaque psoriasis are sharply demarcated
erythematous plaques, covered by silvery white scales, which most commonly
occur on the elbows, knees, scalp, umbilicus, and lumbar area. Children,
adolescents, and adults are affected.
About the Phase IIb study with ponesimod in multiple sclerosis [1,2,3]
A Phase IIb dose-finding study with ponesimod in multiple sclerosis was
successfully completed in July 2011. The study assessed efficacy, safety and
tolerability of three ponesimod dose levels (10 mg, 20 mg or 40 mg) versus
placebo, administered orally once daily for 24 weeks with 464 patients.
In this study, ponesimod significantly reduced the cumulative number of new
active lesions on monthly magnetic resonance imaging (MRI) brain scans
performed from weeks 12 to 24. As compared to placebo, the primary endpoint
was reduced by 43% (p<0.05), 83% (p<0.0001) and 77% (p<0.0001) with ponesimod
10, 20 and 40 mg, respectively.
Ponesimod exhibited an adverse event pattern in this study that, if confirmed
in a Phase III program, would give ponesimod a competitive safety and
tolerability profile.
About S1P receptors
Sphingosine-1-phosphate (S1P) is a sphingolipid released by erythrocytes,
platelets, mast cells and other cell types. It is currently established that
S1P stimulates at least five different cell surface resident G-protein coupled
receptors (GPCRs) - S1P[1,2,3,4,] and [5]. Activation of these GPCRs mediates
a complex variety of biological responses such as lymphocyte migration,
endothelial cell proliferation, blood vessel constriction and heart rate
modulation.
About the selective S1P[1] immunomodulator ponesimod
Ponesimod is an orally active, selective sphingosine 1-phosphate receptor 1
(S1P[1]) immunomodulator. Ponesimod prevents lymphocytes from leaving lymph
nodes, thereby reducing circulating blood lymphocyte counts and preventing
infiltration of lymphocytes into target tissues. The lymphocyte count
reduction is rapid, dose-responsive, is sustained with continued dosing and
quickly reversed upon discontinuation. Ponesimod does not cause
lymphotoxicity: it does not destroy lymphocytes or interfere with their
cellular function. Other blood cells e.g. cells of the innate immune system
are unaffected and remain available to fight off infection. Ponesimod is
therefore considered a promising new oral agent for the treatment of a variety
of autoimmune disorders.
About Actelion and selective S1P[1] immunomodulators
Actelion's efforts in the field of selective S1P[1] receptor immunomodulators
started in 1999 by focusing on GPCRs found on the endothelium, the inner
lining of blood vessels. The result of these research efforts is Actelion's
orally active selective S1P[1] receptor agonist, ponesimod.
References
1. Olsson T, et al; Efficacy and safety of ponesimod, an oral, selective
sphingosine 1-phosphate receptor-1 modulator, in patients with
relapsing-remitting multiple sclerosis: Results from a phase IIb, randomised,
double-blind, placebo-controlled trial. Multiple Sclerosis Journal, 2012; 18
(4 suppl): 49 (152).
2. Freedman M.S, et al; Dose-dependent effect of ponesimod, an oral, selective
sphingosine 1-phosphate receptor-1 modulator, on magnetic resonance imaging
outcomes in patients with relapsing-remitting multiple sclerosis. Multiple
Sclerosis Journal, 2012; 18 (4 suppl): 420 (P923).
3. Fernández Ó, et al; Pharmacodynamic effect, safety and tolerability of
ponesimod, a selective sphingosine 1-phosphate receptor-1 modulator, in
patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis
Journal, 2012; 18 (4 suppl): 417 (P919).
4. Bolli MH et al; 2010; 2-imino-thiazolidin-4-one derivatives as potent,
orally active S1P1 receptor agonists. J Med Chem 53:4198-4211.
5. Matloubian M et al; 2004; Lymphocyte egress from thymus and peripheral
lymphoid organs is dependent on S1P receptor 1. Nature 427:355-360.
6. Piali L et al; 2011; The selective sphingosine 1-phosphate receptor 1
agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J
Pharmacol Exp Ther 337:547-556.
7. Rosen H and Goetzl EJ; 2005; Sphingosine 1-phosphate and its receptors: an
autocrine and paracrine network. Nat Rev Immunol 5:560-570.
Actelion Ltd.
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in
Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally
available dual endothelin receptor antagonist, has been approved as a therapy
for pulmonary arterial hypertension. Actelion markets Tracleer® through its
own subsidiaries in key markets worldwide, including the United States (based
in South San Francisco), the European Union, Japan, Canada, Australia and
Switzerland. Actelion, founded in late 1997, is a leading player in innovative
science related to the endothelium - the single layer of cells separating
every blood vessel from the blood stream. Actelion's over 2,400 employees
focus on the discovery, development and marketing of innovative drugs for
significant unmet medical needs. Actelion shares are traded on the SIX Swiss
Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss
Market Index SMI®).
For further information please contact:
Roland Haefeli
Senior Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
www.actelion.com
The above information contains certain "forward-looking statements", relating
to the company's business, which can be identified by the use of
forward-looking terminology such as "estimates","believes", "expects", "may",
"are expected to", "will", "will continue", "should", "would be",
"seeks","pending" or "anticipates" or similar expressions, or by discussions
of strategy, plans or intentions. Such statements include descriptions of the
company's investment and research and development programs and anticipated
expenditures in connection therewith, descriptions of new products expected to
be introduced by the company and anticipated customer demand for such products
and products in the company's existing portfolio. Such statements reflect the
current views of the company with respect to future events and are subject to
certain risks, uncertainties and assumptions. Many factors could cause the
actual results, performance or achievements of the company to be materially
different from any future results, performances or achievements that may be
expressed or implied by such forward-looking statements. Should one or more of
these risks or uncertainties materialize, or should underlying assumptions
prove incorrect, actual results may vary materially from those described
herein as anticipated, believed, estimated or expected.
Press Release PDF
------------------------------------------------------------------------------
This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.
Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE
HUG#1665730
--- End of Message ---
Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Switzerland
ISIN: CH0010532478;